-
Phase 2 Trial of CXA-10 Recruiting Patients
Yesterday Complexa Inc. announced dosing of the first patient in its Phase 2 clinical trial, PRIMEx. The trial evaluates the safety and efficacy of two doses of the company’s lead candidate, CXA-10 to treat pulmonary arterial hypertension (PAH).
The study includes approximately 45 centers across the United States and Europe. These centers are currently recruiting an anticipated 115 subjects whose involvement will last about five months. Visit the clinical trial’s official website to learn more and find an institution near you.
“We are pleased to advance CXA-10 and continue clinical evaluation of this exciting compound, which has the potential to be a novel first-in-class treatment for patients living with PAH,” Francisco Salva, president and CEO of Complexa, said in a press release.
CXA-10 is an oral nitrated fatty acid (NFA) compound that impacts the fibrotic and inflammatory pathways. NFAs, a novel class of compounds, have demonstrated broad potential to be disease-modifying in many disorders. Complexa’s research builds on a growing trend in PAH drug development that targets inflammation.
“Currently, approved [PAH] treatment options primarily target symptoms without appreciable impact on modifying the underlying disease,” Salva said. “With CXA-10, we have the opportunity to address the unresolved need in PAH.”
Results from the Phase 1 trial gave evidence of CXA-10’s targeted activity, and Phase 1b demonstrated safety and tolerability in all 97 participants.
Do you think you might qualify for this clinical trial? What questions do you have about this new class of treatment for PAH?
-
1 Reply
-
National Jewish Health in Denver is one of the participating sites and my doc is the Principal Investigator for the site. So after very long day (five hours on the road and all day NJH) I came home from my (first) year end tests and assessment with the informed consent paperwork. Logistics will be a problem.
Log in to reply.